Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW MENA SHAROBEEM

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1629389382
CMS profile
210017
Location
GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$24,157.51

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW MENA SHAROBEEM

NPI 1629389382 · CMS profile ID 210017

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629389382?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW MENA SHAROBEEM, NPI 1629389382, CMS profile ID 210017. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629389382?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANDREW MENA SHAROBEEM, NPI 1629389382, CMS profile ID 210017. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629389382?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANDREW MENA SHAROBEEM, NPI 1629389382, CMS profile ID 210017, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1629389382?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $24,157.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $242.6009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954085 CMS
AbbVie Inc. $802.8009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954089 CMS
AbbVie Inc. $125.0009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954093 CMS
AbbVie Inc. $451.8409/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954071 CMS
AbbVie Inc. $223.1209/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954075 CMS
Lilly USA, LLC $16.6209/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031249791 CMS
ANI Pharmaceuticals, Inc. $19.3509/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034109633 CMS
PFIZER INC. $17.8809/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050560629 CMS
Lilly USA, LLC $16.7908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031256865 CMS
Janssen Biotech, Inc. $24.4108/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988167611 CMS
Amgen Inc. $11.6508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802551 CMS
Amgen Inc. $13.6408/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802547 CMS
PFIZER INC. $17.5708/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050655707 CMS
Amgen Inc. $5.5208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802509 CMS
Ferring Pharmaceuticals Inc. $19.5508/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044239649 CMS
UCB, Inc. $39.0208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021430667 CMS
AstraZeneca Pharmaceuticals LP $15.4308/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014565895 CMS
Lilly USA, LLC $19.1408/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031249789 CMS
Kyowa Kirin, Inc. $27.4708/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026985901 CMS
ANI Pharmaceuticals, Inc. $22.7108/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034105679 CMS
AbbVie Inc. $22.8508/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954067 CMS
AbbVie Inc. $25.0508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954063 CMS
AstraZeneca Pharmaceuticals LP $13.5508/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011623145 CMS
UCB, Inc. $47.2808/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021430697 CMS
Amgen Inc. $16.7608/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802501 CMS
PFIZER INC. $17.2408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050655703 CMS
AbbVie Inc. $15.1207/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954059 CMS
PFIZER INC. $15.3707/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050639679 CMS
UCB, Inc. $40.9706/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021430683 CMS
GlaxoSmithKline, LLC. $61.5906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003487427 CMS
Lilly USA, LLC $13.1306/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031258039 CMS
Genentech USA, Inc. $24.0206/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040297923 CMS
Radius Health, Inc. $19.2706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024680067 CMS
Janssen Biotech, Inc. $18.1306/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988167650 CMS
Janssen Biotech, Inc. $18.2406/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988167641 CMS
AbbVie Inc. $24.7406/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954055 CMS
Horizon Therapeutics plc $125.4106/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987074253 CMS
GlaxoSmithKline, LLC. $20.7606/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003486645 CMS
PFIZER INC. $13.7706/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050415517 CMS
AbbVie Inc. $25.1706/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954047 CMS
AbbVie Inc. $26.2806/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954051 CMS
Janssen Biotech, Inc. $22.1806/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988167695 CMS
PFIZER INC. $16.5605/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049556311 CMS
Novartis Pharmaceuticals Corporation $22.4705/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993403225 CMS
Amgen Inc. $23.4805/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802524 CMS
Lilly USA, LLC $16.1005/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031257087 CMS
Novartis Pharmaceuticals Corporation $13.6805/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993403223 CMS
PFIZER INC. $13.2905/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050557981 CMS
AstraZeneca Pharmaceuticals LP $17.7705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012058891 CMS
AbbVie Inc. $29.9005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998954043 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $45,928.67 197
PY2020 $14,714.05 157
PY2021 $12,562.82 196
PY2022 $32,095.81 213
PY2023 $24,157.51 159
PY2024 $47,350.27 147
PY2025 $53,796.07 171

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,797,822.45 35
PY2024 Recipient $29,100.58 2
PY2024 Principal investigator $1,447,514.79 20
PY2023 Principal investigator $463,030.22 5
PY2022 Principal investigator $48,344.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $161.00 12/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531314
Principal investigator 1 ABBVIE INC. $39.00 12/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531316
Principal investigator 1 ABBVIE INC. $3,009.65 12/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526700
Principal investigator 1 ABBVIE INC. $39.00 11/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525476
Principal investigator 1 ABBVIE INC. $680.00 11/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525250
Principal investigator 1 ABBVIE INC. $39.00 11/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524357
Principal investigator 1 ABBVIE INC. $118.00 11/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524075
Principal investigator 1 ABBVIE INC. $12,349.10 11/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520295
Principal investigator 1 ABBVIE INC. $39.00 10/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202517157
Principal investigator 1 ABBVIE INC. $5,440.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503671
Principal investigator 1 ABBVIE INC. $8,160.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504061
Principal investigator 1 ABBVIE INC. $39.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504063
Principal investigator 1 ABBVIE INC. $4,760.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504065
Principal investigator 1 ABBVIE INC. $3,020.45 08/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202502194
Principal investigator 1 ABBVIE INC. $78.00 07/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500160
Principal investigator 1 Amgen Inc. $331.91 07/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246639285
Principal investigator 1 ABBVIE INC. $9,062.70 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,435.80 06/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280666
Principal investigator 1 ABBVIE INC. $3,500.00 05/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485847
Principal investigator 1 ABBVIE INC. $184.00 05/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202484405
Principal investigator 1 ABBVIE INC. $7,394.95 05/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481727
Principal investigator 1 ABBVIE INC. $783.00 04/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202477729
Principal investigator 1 ABBVIE INC. $302.00 04/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202476283
Principal investigator 1 ABBVIE INC. $9,342.65 04/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473883
Principal investigator 1 ABBVIE INC. $238.00 03/27/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202466930
Principal investigator 1 ABBVIE INC. $600.00 03/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202463542
Principal investigator 1 ABBVIE INC. $12,858.05 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202458233
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,105.00 02/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223275693
Principal investigator 1 Eli Lilly and Company $6,015.00 02/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
TALTZ PSA OBSERVATIONAL STUDY No dispute reported 06/30/2026 1187877141
Principal investigator 1 ABBVIE INC. $3,193.25 02/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444505
Principal investigator 1 Eli Lilly and Company $2,087.70 01/27/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187874187
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,996.85 01/15/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH, PLLC
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190313257
Principal investigator 1 Eli Lilly and Company $118,617.00 01/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187874367
Principal investigator 1 Amgen Inc. $1,554,750.54 01/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639319
Principal investigator 1 ABBVIE INC. $3,052.85 01/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202434152